NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022

Rhea-AI Summary

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, will report its first quarter 2022 financial results on May 16, 2022, before the market opens. The company will host a conference call at 8:30 AM ET to discuss these results along with clinical and corporate updates. Investors can participate by submitting questions via email by 4:00 PM ET on May 13, 2022. The company is advancing treatments for COVID-19 and severe bipolar depression, with investigational products ZYESAMI® and NRX-101 receiving FDA designations.

--Company to Host Conference Call May 16, 2022, at 8:30AM ET--

RADNOR, Pa., May 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022. The company will host a conference call and webcast on May 16, 2022, 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at rsheffield@nrxpharma.com by 4:00 PM Eastern Time on May 13, 2022.

The company will host a conference call/webcast 5/16/22, @8:30 AM ET to discuss results and provide a corporate update.

Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (877) 407-9716 (U.S.), (201) 493-6779 (International) Conference ID: 13729829, or through the webcast link NRx Pharmaceuticals First Quarter 2022 Earnings Call. A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company") draws upon decades of collective, scientific, and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI® (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is in a Phase III trial for Critical COVID-19 patients which is sponsored and managed by the US National Institutes of Health. The FDA has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy.

NRx Pharmaceuticals is led by executives and board members who have held senior roles at Lilly, Pfizer, GSK and the FDA. NRx Pharmaceuticals was co-founded by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in various biotechnology startup companies and been appointed to advisory roles in four U.S. Presidential Administrations. The NRx Pharmaceuticals' board includes Dr. Sherry Glied, former U.S. Assistant Secretary for Health (ASPE), Chaim Hurvitz, former director of Teva and President of the Teva International Group, General H.R. McMaster, Ph.D. (US Army, Ret.), the 26th United States National Security Advisor, and Daniel E. Troy, J.D., former Chief Counsel of the FDA.

Cautionary Note Regarding Forward-Looking Statements

This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management.  

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise.  Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above. 

CORPORATE CONTACT		INVESTOR RELATIONS
Molly Cogan		Tom Johnson, Director
Senior Director, Global Communications		LifeSci Advisors
mcogan@nrxpharma.com		tjohnson@lifesciadvisors.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-first-quarter-2022-results-on-may-16-2022-301543608.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When will NRx Pharmaceuticals report its first quarter 2022 results?

NRx Pharmaceuticals will report its first quarter 2022 financial results on May 16, 2022.

What time is the NRx Pharmaceuticals conference call on May 16, 2022?

The conference call will be held at 8:30 AM ET on May 16, 2022.

How can investors submit questions for the NRx Pharmaceuticals conference call?

Investors can submit questions via email to the investor relations representative by 4:00 PM ET on May 13, 2022.

What is ZYESAMI® and its significance for NRx Pharmaceuticals?

ZYESAMI® (aviptadil) is an investigational product for COVID-19 that has received Fast Track designation from the FDA.

What other investigational therapies is NRx Pharmaceuticals working on?

NRx Pharmaceuticals is also developing NRX-101, a treatment for severe bipolar depression, which has received Breakthrough Therapy designation from the FDA.